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Several biological activities of pomegranate have been widely described in the literature, but the anti-inflammatory effect in the
gastrointestinal tract has not been reviewed till now. The aim of the present paper is to summarize the evidence for or against the
efficacy of pomegranate for coping with inflammatory conditions of the gastro-intestinal tract. The paper has been organized in
three parts: (1) the first one is devoted to the modifications of pomegranate active compounds in the gastro-intestinal tract; (2)
the second one considering the literature regarding the anti-inflammatory effect of pomegranate at gastric level; (3) the third part
considers the anti-inflammatory effect of pomegranate in the gut. In vivo studies performed on the whole fruit or juice, peel, and
flowers demonstrate antiulcer effect in a variety of animal models. Ellagic acid was the main responsible for this effect, although
other individual ellagitannins could contribute to the biological activity of the mixture. Different preparations of pomegranate,
including extracts from peels, flowers, seeds, and juice, show a significant anti-inflammatory activity in the gut. No clinical studies
have been found, thus suggesting that future clinical studies are necessary to clarify the beneficial effects of pomegranate in the
gastrointestinal tract.
1. Introduction
Punica granatum L. (pomegranate, Family Lythraceae) is a
deciduous tree distributed throughout the world. Pomegran-
ate (PG) fruit, in the form of extract of juice, is widely
promoted to consumers since the nineties as medicinal food
in the United States and Europe; as a consequence, a large
number of pomegranate-containing products have recently
been introduced into the USA and European market and are
widely sponsored as healthy products.
PG is used in the traditional medicine of different Asian
cultures for the treatment of a variety of ailments. In India,
Tunisia, and Guatemala, dried PG peels are decocted and
employed both internally and externally as astringents and
germicides and used for treating aphthae and diarrhoea. In
Ayurvedic medicine the plant, described under its Sanskrit
name “dadima” (fruit), is considered as a “blood purifier”
and used to cure parasitic infections (for a review, see [1]),
and the decoction of the root is considered helpful against
fevers and chronic debility due to malaria. Punica granatum
L. fruit rind is traditionally used in the eastern province
of Orissa (India), an area endemic for both Plasmodium
falciparum and Plasmodium vivax, against malaria; in this
regard, the beneficial effect of the fruit rind of PG for
the treatment of malaria has been recently ascribed to the
antiparasitic activity [2] and to the inhibition of the proin-
flammatory mechanisms involved in the onset of cerebral
malaria [3].
The biological activity of PG has beenwidely investigated,
including in vitro, in vivo, and clinical studies. The bene-
ficial effects are mostly the cardiovascular protective role,
neuroprotective activity, hypoglycemic effect, and anticancer
properties, in particular against prostate, colon, and breast
cancer; the anticancer effect is limited only to in vitro and
animal studies [1, 4, 5].
The gastrointestinal tract represents an important barrier
between the human hosts and microbial populations. One
potential consequence of host-microbial interactions is the
development of mucosal inflammation, which can lead to
gastritis and ulcer.
2 Evidence-Based Complementary and Alternative Medicine
Gastritis is defined as inflammation of the gastricmucosa.
There are several etiological types of gastritis, differing for
clinical manifestations and pathological features. Gastritis
can be caused by endogenous and exogenous factors, includ-
ing acid, pepsin, stress, and noxious agents such as alcohol,
nonsteroidal anti-inflammatory drug (NSAIDs), Helicobac-
ter pylori (H. pylori) infection, and smoking. H. pylori,
a Gram-negative bacterium that colonizes the stomach of
humans and primates, is the most responsible pathogen
for these inflammatory processes. H. pylori infection in
humans represents a serious public health concern: the
WHO classifies this bacterium as a Type 1 carcinogen.
The clinical course of H. pylori infection is highly variable
and is influenced by both microbial and host factors. The
pattern and distribution of gastritis strongly correlate with
the risk of clinical duodenal or gastric ulcers, mucosal
atrophy, gastric carcinoma, or gastric lymphoma. It has been
demonstrated that gastric epithelial cells, after H. pylori
infection, show higher levels of cytokines including IL-
1𝛽, IL-6, TNF-𝛼, and IL-8, a potent neutrophil-activating
chemokine that apparently plays a central role in gastric
diseases [6, 7]. H. pylori strains carrying the Cag-PAI (Cag
Pathogenicity Island) induce a far stronger IL-8 response
than Cag-negative strains, and this response depends on
activation of NF-𝜅B and the early-response transcription
factor Activating Protein-1 (AP-1) [8]. IL-21 is constitutively
expressed in gastric mucosa as well and is more abun-
dant in biopsy specimens from H. pylori-infected patients
[9].
Inflammatory bowel diseases (IBDs), among which
Crohn’s disease (CD) and ulcerative colitis (UC), are the
most common inflammatory-related diseases in the gut;
IBDs occur in response to genetic or environmental fac-
tors and are characterized by the uncontrolled response of
the intestinal immune system against the normal enteric
microflora, leading to abdominal pain and chronic diarrhoea.
All components of the gut, including the epithelial barrier,
the mucosal immune system, and stromal/supportive cells,
participate in the intestinal immune response. Immune and
nonimmune cells, that is, epithelial, endothelial, mesenchy-
mal, and nerve cells, exchange regulatory signals via the
production ofmediators (cytokines, growth factors, adhesion
molecules, etc.), which facilitate and amplify cell interactions
and inflammation [10].
Epithelial cells, in response to a proinflammatory stim-
ulus, that is, TNF𝛼 and bacteria, release several cytokines
and induce the expression of NF-𝜅B related genes such as
cyclooxygenase-2 (COX-2), inducible nitric oxide synthase
(iNOS) and metalloprotease-9 (MMP-9) [11]. The integrity
of the epithelial barrier is reduced thus favouring pathogen
infections. NF-𝜅B is highly involved in the control of the
transcription of the inflammatory mediators.
Anti-inflammatory properties of PG and its major com-
ponents have been widely described in the literature (for
a review, see [12]). For example, cold pressed PG seed oil
has been shown to possess anti-inflammatory activity since
it inhibited in vitro both cyclooxygenase and lipoxygenase
enzymes. In addition, the acetone extract of whole PG fruit
inhibited phosphorylation of several cytokines released by
UV-B-irradiated keratinocytes, and the mechanism underly-
ing this effect was found to be NF-𝜅B-dependent [13].
Although some papers describe the beneficial effects of
this fruit against gastro-intestinal inflammation, surprisingly
this has not been reviewed till now.
The aimof the present paper is to summarize the evidence
for or against the efficacy of PG for addressing inflammatory
conditions of the gastro-intestinal tract.
The paper will be divided in three parts: (1) the first one
will be devoted to the modifications of PG active compounds
in the gastro-intestinal tract, with particular attention to
the intestinal metabolites; (2) the second one considers the
literature regarding the anti-inflammatory effect of PG and
individual compounds at gastric level; (3) the third part
considers the anti-inflammatory effect of PG and individual
compounds in the gut, taking into account also the main
metabolites which are formed by microbial biotransforma-
tion after PG consumption.
2. Pomegranate Composition and Metabolism
in the Gastrointestinal Tract
PG has been shown to contain more than 100 different
phytochemicals, and a substantial part of them contributes to
the antioxidant activity elicited by the extracts [14]. However,
several variables, such as the harvesting season, soil, and the
kind of extract, can deeply affect chemical composition and
consequently the biological activity.
Ellagitannins (ETs) and anthocyanins (ANs) represent
the most abundant polyphenols in PG juice. ETs constitute
a complex class of polyphenols characterized by one or
more hexahydroxydiphenoyl (HHDP) moieties esterified to
a sugar, usually glucose. ETs content in PG juice is around
1500–1900mg/L [15]. This part of the fruit contains several
ETs typical of PG such as punicalagins, and other minor
tannins including punicalin and gallagic acid. Punicalagins
are unique to PG, and possess amolecular weight greater than
1000. During the juice processing, the whole fruit is pressed,
and ETs are extracted into PG juice in significant amount,
reaching levels over 2 g/L [15]. PG fruit contains also a small
amount of free ellagic acid (EA), and it has been estimated to
be around 15mg/L in fresh arils [15].
ETs are quite stable under the physiological conditions of
the stomach. The acid conditions (HCl, pH 1.8–2.0) and the
gastric enzymes do not hydrolyse the native ETs to ellagic
acid, and no degradation of ETs has been observed. The
stomach seems to be a location for the absorption of free
EA, but ETs are not absorbed [16]. PG ETs release EA in
the gut, and this compound is poorly absorbed in the small
intestine; conversely, EA is largely metabolized by human
gut microflora in the intestinal lumen into urolithins, such
as urolithins A and B, and urolithin-8-methyl ether [17,
18]. These metabolites reach relevant plasma concentrations
(3–5𝜇M) after PG juice consumption [19]. The absorbed
metabolites are conjugated with glucuronic acid and/or
methylated to give ether derivatives [16].
In addition to ETs, PG fruit is an important source of ANs
as well; these include the 3-glucosides and 3,5-diglucosides
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of delphinidin, cyanidin, and pelargonidin [15, 20]. The total
amount of ANs in PG fruit is higher in fresh arils than in
the frozen ones (306 versus 172mg/L, resp.), and in single-
strength commercial juice than in commercial juice from
concentrate (387 versus 162mg/L, resp.) [15].
The pH of the stomach (1-2) ensures that ANs are
maintained as the flavylium cation, which is the most stable
formofANs.The stability ofANs under the gastric conditions
has been confirmed by in vitro studies [20, 21]. Conversely,
the neutral pH of the small and large intestines makes ANs
much less stable, and these molecules are converted into
a variety of metabolites [22]. Several studies reported that
exposure of different ANs to gut microflora resulted in rapid
deglycosylation and demethylation to the corresponding
aglycones. The aglycones were unstable at neutral pH and
rapidly degraded to their corresponding phenolic acids and
aldehydes through cleavage of the C-ring. Similar results
were obtained after incubation of free and acylated ANs with
human faecal microbiota [23, 24]. It has been proposed that
the decrease of anthocyanin concentration after pancreatin
bile salt digestion (as a simulation of small intestine digestion)
could be partially explained by the transformation of the
flavylium cation to the chalcone at the neutral pH [20];
however these hypotheses need to be confirmed by in vivo
studies.
3. Effect of Pomegranate in
Gastric Inflammation
There are no clinical studies in the literature investigating the
beneficial effect of PG in the stomach.The anti-inflammatory
activity of PG at gastric level has been evaluated mainly by
in vivo studies, and few in vitro studies deal with the anti-H.
pylori activity of PG extracts and individual compounds. For
a better comprehension of the effects of PG in modulating
gastric inflammation, in the following paragraph the in vivo
studies have been organized according to the inflammatory
challenge applied to induce gastritis in animal models.
3.1. In Vitro Studies. A small number of studies report
that PG is able to treat H. pylori infection. Methanol peel
extract of PG exhibited a remarkable anti-H. pylori activity
in vitro, as shown by the size of inhibition zone in the disk
diffusion method, which was comparable to the reference
compound metronidazole (MIC 8𝜇g/mL) [25]. In another
study the methanolic extract of PG fruit rind exhibited high
activity against H. pylori strains (39mm inhibition zone
for 100 𝜇g disc−1) in comparison with other plant extracts
[26]; in particular eight among nine PG cultivars showed
high activity against this bacterium (mean of inhibition zone
diameter ranging from 16 to 40mm at 50 𝜇g disc−1). Strong
anti-H. pylori activity of PG ethanolic extract from pericarp
has been also documented, and the highest zone of inhibition
(16.5mm) was found at 2.5mg disc−1 [27].
Indeed, further studies with PG extracts alone and com-
bined with drugs commonly used for H. pylori eradication
should be carried out before considering PG as effective
antimicrobial agent.
3.2. Animal Studies
Ethanol-Induced Gastritis. Ethanol-induced ulcers are the
result of a direct effect of ethanol on gastric mucosa, mostly
due to its capacity to induce necrosis of superficial gastric
epithelial cells and erosion [28]. An in vivo study showed
that PG fruit rind methanolic extract showed a significant
reduction in the ulcer index (UI) in ethanol-induced gastritis
in rats; the extract, when tested at 250mg/kg and 500mg/kg,
inhibited UI by 21% and 63%, respectively, whereas the
reference compound ranitidine (50mg/kg) showed 51% inhi-
bition. Rats treated with 500mg/kg of PG extract were also
protected from intraluminal bleeding [29]. In another study,
the hydroalcoholic extract (methanol : water 80 : 20) from
dried flowers of PG significantly reduced the UI (−87.5%
at 980mg/kg), whereas the half dose (490mg/kg) and
omeprazole (20mg/kg) exhibited 65% and 49.6% inhibition,
respectively [30].
Some biochemical parameters, such as superoxide dis-
mutase (SOD), catalase, tissue lipid peroxidation, and glu-
tathione peroxidase (GSH-PX), were reduced in animals
treated with acetylsalicylic acid and returned at the basal
levels in animals that received the fruit rind methanolic
extract [29]. PG tannins significantly inhibited ethanol-
inducedmucosal injury in a dose-dependentmanner, and the
effect was ascribed to the decrease of lipid peroxidation as
well as NO levels and to the modulation of both SOD and
GSH-PX in gastric mucosa [31].
Gharzouli et al. demonstrated that aqueous extract of
PG peel (AEP) shows a gastroprotective effect in rats
with ethanol-induced gastric lesions [32]. The simultaneous
administration of ethanol and AEP significantly decreased
gastric lesions and UI (from −53.7% to −76.9%).
Among the pure compounds, Beserra et al. demonstrated
that the oral pretreatment with EA (3, 10, and 30mg/kg)
significantly reduced gastric injury by 59, 79, and 70%, respec-
tively, whereas the inhibitory effect by ranitidine (50mg/kg)
was −83% [33].
Nonprotein sulfhydryls (NP-SH) are antioxidant com-
pounds involved in the maintenance of gastric integrity.They
control the cascade of inflammatory cytokines and promote
detoxification and excretion of ROS produced mainly by
noxious agents and stress. Pretreatment with EA (3 and
10mg/kg) significantly increased the NP-SH content in rats
thus suggesting a protective role of EA against ethanol-
induced gastritis [33].
TNF-𝛼 released by monocytes/macrophages plays a key
role in initiating the cascade of other proinflammatory
cytokines, including IL-1𝛽, IL-6, and IFN-𝛾, which are impor-
tant biomarkers in gastric inflammation. Rats subjected to
ethanol-induced ulcer after treatment with EA (10mg/kg)
showed levels of TNF𝛼 significantly lower than the ethanol-
treated group (11.1 ± 1.1 versus 6.2 ± 1.0 pg/mL, resp.) [33].
NO is considered to be one of the most important
defensive endogenous agents in the gastric mucosa. Pre-
treatment with inhibitors of NO synthase such as L-NAME
has been demonstrated to worsen the ethanol-induced ulcer.
Rats pretreated with L-NAME increased the severity of
the gastric lesions induced by ethanol, whereas treatments
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with L-arginine, in the absence or in the presence of EA,
significantly attenuated the deleterious effect of L-NAME
(−22% and −19.6%, resp.). When EA was coadministrated
with L-arginine, the gastroprotective effect was found 2-fold
higher (−39%) with respect to EA alone [33].
NSAIDs-Induced Gastritis. Nonsteroidal anti-inflammatory
drugs (NSAIDs), such as acetylsalicylic acid, indomethacin,
and ibuprofen, are commonly used as analgesics in many
acute and chronic inflammatory conditions. Acetylsali-
cylic acid interferes with gastric protective mechanisms,
such as mucus and bicarbonate secretion, surface epithe-
lial hydrophobicity, and mucosal blood flow. Acetylsalicylic
acid mainly interferes with the biosynthesis of cytopro-
tective prostaglandins through the inhibition of cyclooxy-
genase (COX); this effect results in an over production
of leukotrienes and other products of the 5-lipoxygenase
pathway.
PG hydroalcoholic extract (methanol 70%) from pow-
dered rind showed a significant UI reduction in rats treated
with 400mg/kg acetylsalicylic acid. The inhibitory effect
showed by PG extract, at 250 and 500mg/kg, was−22.4% and
−74.2%, respectively, whereas ranitidine (50mg/kg) showed
44.7% inhibition [29]. In another study, the hydroalcoholic
extract (methanol : water 80 : 20) obtained from powdered
flowers of PG, when tested at 980mg/kg and 490mg/kg,
inhibited ulceration by 83.9% and 73.8%, respectively, thus
suggesting that PG flowers contain compounds with a dose-
dependent gastric protective effect [30].
Prostaglandins produced by COX-1, mainly PGI
2
and
PGE
2
, are essential for gastric mucosa protection. The
ulcerogenic effect of NSAIDs seems to be related to the
inhibition of endogenous prostaglandin synthesis, although
it has also been established that indomethacin modifies
other protectivemechanisms of the gastricmucosa, including
gastric secretion and the permeability of the gastric mucosal
barrier [34]. Indomethacin is known to increase leukotriene
C
4
and reduces PGE
2
levels. Enhancement of leukotriene
synthesis results in damaging effects, which may induce
mucosal vasoconstriction, and enhances NSAIDs-induced
injury [35].
Hydroalcoholic (methanol : water 80 : 20) extract from
powdered flowers of PG (980mg/kg) showed significant pre-
vention of gastric lesions in indomethacin-treated rats, higher
inhibition of ulceration (83.9%), and reduced gastric acid
secretion in comparison with omeprazole 20mg/kg (69.5%).
Although pure compounds were not tested during this study,
the authors suggest that the anti-ulcerogenic activity of the
extract may be due to the presence of saponins, tannins, and
flavonoids [30].
The treatment with EA (3, 10, and 30mg/kg) significantly
decreased UI by 82, 74, and 77%, respectively, whereas the
inhibitory effect, after treatmentwith cimetidine (100mg/kg),
was 88% [33]. Leukotriene B
4
(LTB
4
) contributes to the
NSAID gastric injury by promoting intense chemotaxis of
the neutrophils and leukocyte adherence to the vascular
endothelium. Plasma levels of LTB
4
were also reduced with
the treatment of EA (3, 10, and 30mg/kg), but levels of
prostaglandin E
2
(PGE
2
) in gastric mucosa were not affected
[33]. In another study, treatment with EA or omeprazole for
3 days significantly upregulated the mucosal PGE
2
level by
2.0- and 1.6-folds, with respect to the untreated group [36]. In
the same study, indomethacin-administered mice increased
mucosal myeloperoxidase (MPO) activity on the third day.
Treatment with EA (7mg/kg once daily for 3 days, orally)
and omeprazole significantly reduced MPO activity by 77.9%
and 68,1%, respectively. Ulceration significantly depleted the
expression of gastric COX-1. In this study, COX-2 expression
was not significantly modified by indomethacin treatment;
conversely, EA significantly increased COX-1 and COX-2
expression in the ulcerated group [36].
The same study investigated the effect of EA on indo-
methacin-induced cytokines release in the gastric mucosa.
Indomethacin administration increased the release of several
cytokines, including TNF-𝛼 (1.8-fold), IL-1𝛽 (1.9-fold), and
decreased IL-4 (2.3-fold), IL-10 (1.2-fold), VEGF (1.7-fold),
EGF (1.6-fold), and HGF (1.5-fold), whereas IL-6 secretion
was not affected. EA (7mg/kg) significantly reduced the
proinflammatory cytokines (TNF-𝛼, IL-1𝛽, and IL-6) release
by 1.9-, 1.5-, and 1.6-folds, respectively; a significant increase
was seen for the anti-inflammatory cytokines IL-4 and IL-
10 levels and growth factors (VEGF, EGF, and HGF) levels.
When EA was administrated to the animals, it was able to
decrease TNF𝛼, IL-1𝛽, and IL-6 release, and an increase of IL-
4 and IL-10was observed.WhenEAwas given followingCOX
inhibitor pretreatment (celecoxib, NS398), the protective
effect was partially missed [36].
Acetic Acid-Induced Gastritis. No studies dealing with the
effect of PG extracts on acetic acid-induced gastritis are
present in the literature, whereas some studies on the
pure compound EA occur. Treatment with EA (3, 10, and
30mg/kg) for 14 days did not reduce the ulcerated area
caused by application of acetic acid, but showed a sig-
nificant reduction in the ulcer thickness (−21,3%, −25,6%,
and −26,2%, resp.) in comparison to the vehicle group.
Cimetidine significantly reduced the ulcerated area and the
thickness of the ulcer by 33.4% [33].
In acetic acid ulcer model the plasma levels of TNF𝛼
were significantly lower in animals treated with EA at the
dose of 3mg/kg with respect to the control group (8.8 versus
19.3 pg/mL, resp.) [33]. IL-4 is an anti-inflammatory cytokine
able to exacerbate, if excessively released, the inflammatory
injury in the stomach. It has been demonstrated that ulcera-
tion drastically increased the plasma levels of IL-4 by 6-fold,
and co-administration with EA significantly suppressed the
increase by 65.0%, 60.6%, and 44.2% at 3mg/kg, 10mg/kg,
and 30mg/kg, respectively [33]. In a similar fashion, ulcer-
ation increased the plasma levels of IL-6 by 12.5-fold as
compared to the control group, and EA significantly inhibited
IL-6 levels by 75%, 73%, and 48% at 3mg/kg, 10mg/kg, and
30mg/kg, respectively.The same trendwas observed for IFN-
𝛾. Acetic acid ulceration significantly increased the levels of
IFN-𝛾 by 7.2-fold, as compared to the control group. Pre-
treatment with the three concentrations of EA significantly
inhibited the IFN-𝛾-induced gastritis by 83.8%, 63%, and
54%. IL-1𝛽, IL-10, and VEGF levels were undetectable on the
14th day of ulcer induction in this model of gastritis [33].
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Pylorus-Ligated Gastritis. The hydroalcoholic (methanol :
water 80 : 20) extract of PG flowers demonstrated significant
reduction in volume of gastric acid secretion and total acidity
of gastric juice in rats with pylorus-ligated gastritis, whereas
pH of gastric juice increased. Administration of the extract
(980mg/kg) was found to reduce the volume of gastric
acid up to 40.0% as compared to the control group; the
reduction of the gastric volume (−24.4%) was present also
when the extract was given at the lower dose (490mg/kg)
[30]. In another study, PG tannins significantly increased the
secretion of adherent mucus and free mucus, but did not
affect the free acidity, total acidity, gastric juice volume, and
gastrin pepsin activity induced by pylorus ligation [31].
PG hydroalcoholic extracts (ethanol 50%) from peel
(100mg/kg), rind (500mg/kg), and seed (500mg/kg) signif-
icantly decreased the mucosal injury at the 6th day of treat-
ment, showing the antiulcer effect [37]. In the same study, EA
reduced gastric acid secretion to 65–70% in pylorus-ligated
rats after intraperitoneal administration at 5 and 10mg/kg,
although the effect was not statistically significant. On the
contrary, acidity was significantly reduced by EA (5mg/kg)
treatment [38].
Gastric Ischemia/Reperfusion. Gastric ischemia induced for
20 minutes by bleeding from the carotid artery produced
a marked reduction of gastric mucosal blood flow (GMBF)
up to 40–50% of basal values. The GMBF then increased
over basal values during 15 minutes reperfusion, reaching
a maximum of 140–160% before gradually returning to the
basal levels. Rats treated with EA (6mg/mL) or SOD (15000
unit/kg/hr) did not show any differences in GMBF with
respect to the control group [39].
Reduction of hemorrhagic lesions following gastric
ischemia/reperfusion significantly started at 3mg/mL of
EA. The increased levels of lipid peroxidation induced by
ischemia/reperfusion was significantly inhibited when ani-
mals were pretreated with either EA (6mg/mL) or SOD
(15000 unit/kg/hr), the inhibition being 78.3% and 82.6%,
respectively [39].
In another study, topical application of NH
4
OH (60mM)
produced a persistent reduction of gastric potential difference
in the stomach made ischemic by bleeding and resulted
in hemorragic damage 1 hr later. The development of gas-
tric lesions induced by NH
4
OH plus ischemia was dose-
dependently inhibited by preexposure of the mucosa to
EA (1–6mg/mL), and a significant effect was observed at
concentrations above 3mg/mL [30].
Stress-Induced Gastritis. No studies investigating the effect
of PG extracts against stress-induced gastritis have been
published so far. Murakami et al. report that EA significantly
inhibited the occurrence of stress-induced gastric lesions at
5mg/kg [38], whereas the effect of the other pure compounds,
including ETs and ANs, was not investigated.
4. Effect of Pomegranate in
Intestinal Inflammation
Anti-inflammatory properties of PG and its major compo-
nents have been widely described in the literature (for a
review, see [12]). However only few papers reported the effect
on intestinal inflammation, and, surprisingly, no clinical
studies are present in this regard. In the following paragraph,
the in vitro and in vivo anti-inflammatory effect of Punica
granatumL. extracts and individual compounds at the intesti-
nal level will be reviewed and discussed.
4.1. In Vitro Studies
PG Juice and Peel/Husk Extract. The anti-inflammatory effect
of PG on an in vitro intestinal model was firstly described
in 2006 in a study investigating the molecular mechanisms
underlying its antitumoral properties [40]. It was demon-
strated that pretreatment of a colon cancer cell line with
commercial PG juice (6–50 𝜇g/mL), total pomegranate tan-
nins (TPT, 30–200𝜇g/mL), and punicalagin (25–200𝜇g/mL)
inhibited AKT activity, NF-𝜅B activation, and COX-2 expres-
sion induced by TNF𝛼 [40]. PG juice showed the highest
activity on these parameters with respect to TPT and the
pure component, indicating that more than a single bioactive
compound contributes to the biological activity exerted by
the extract. Using a different cellularmodel (human intestinal
Caco-2 cells), Romier-Crouzet et al. demonstrated that the
pretreatment with a polyphenolic aqueous extract from PG
peels (PomH) reduced many inflammatory mediators [41].
The extract, at the concentration of 50 𝜇M (expressed as
total phenols), significantly inhibited the secretion of the
chemokine IL-8 and the production of NO upon stimu-
lation by IL-1𝛽 or a mixture of proinflammatory stimuli.
It also exhibited an inhibitory effect on the secretion of
PGE
2
by COX-1 as well as COX-2 in response to IL-1𝛽
stimulation [41]. Authors explained this anti-inflammatory
activity with the inhibition of NF-𝜅B activation and ERK-1/2
phosphorylation; both systems are implicated in IL-8, NO,
and PGE
2
expression [41]. The same group demonstrated
that pretreatment with PG husk extract (PomH, 100 𝜇g/mL)
and its pure ellagitannin punicalagin (50 𝜇M) could modify
transcription levels of the genes encoding for IL-6 and MCP-
1 in differentiated Caco-2 cells treated with a mixture of
proinflammatory stimuli (IL-1𝛽, TNF-𝛼, IFN-𝛾, and LPS)
[42]. No effect was seen in the absence of proinflammatory
conditions and on IL-8 expression, while PomH as well
as punicalagin decreased the secretion of IL-8, IL-6, and
MCP-1 [42]. A direct interaction between punicalagin and
cytokines was also demonstrated, thus suggesting that PomH
ETs could interact with the proinflammatory cytokines in the
gut lumen, decreasing the intercellular communication and
limiting the local and systemic inflammation [42].
PG Metabolites and Urolithins. Phenolic compounds con-
tained in PG extracts are of particular importance during
intestinal inflammation. In fact, it was demonstrated that only
a very small percentage of polyphenols ingested with diet
are absorbed in the small intestine, while the majority of
them remain in the gut lumen, where they counteract and are
metabolized by gut microbiota. In this regard, it was shown
that, after a digestion in vitro, ANs, phenolic compounds, and
vitamin C present in PG juice diminish their solubility, com-
promising the amount of compounds that can be absorbed
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by intestinal cells and their bioavailability [20]. However, this
permanence of phenolic compounds ingested with PG in the
intestinal lumen enhances the interactions with gut micro-
biota. Many scientific evidence points out the importance of
human gut microbiota toward health improvement and the
genesis of various diseases. In fact beneficial bacteria species,
as Bifidobacterium and Lactobacillus, constitute an important
barrier against the overgrowth of external and internal
pathogenic strains, whose prevalence causes chronic and
acute bowel diseases and has been associated with aging and
cancer [43]. For this reason, themodulation of gutmicrobiota
by dietary supplements and food intake is of key importance
to the maintenance of physiological balance. In this regard, a
commercial PG dietary supplement derived from extraction
of residual material from juice production (PomX) and puni-
calagin demonstrated a selective toxicity toward intestinal
pathogenic bacteria as compared to probiotic bacteria [44]. In
particular, PomX, as well as punicalagin and EA, significantly
inhibited Clostridium and Staphylococcus aureus growth.
Punicalagin showed an inhibitory effect also against the
growth of Escherichia coli and Pseudomonas aeruginosa (IC
50
9.2 and 3.2 𝜇M, resp.). Probiotic lactobacilli were unaffected
by PG components, while the positive effect on bifidobacteria
was species-specific [44]. Possible explanations of themecha-
nisms underlying the antimicrobial effect against pathogenic
bacteria have been hypothesized: (i) tannins could create
stable complexes with proteins or with physiological metal
ions essential for bacteria survival; (ii) polyphenols might
decrease the pH of intestinal environment, favouring the
growth of probiotic instead of pathogenic bacteria [44]. The
long permanence (up to 56 hrs in the colon before excretion
[45]) of PG ellagitannins and the interaction with gut micro-
biota lead to the formation of many metabolites, that could
explicate different biological activities at this level. Through
in vitro batch-culture fermentation system the effect of PomX
extract and punicalagin on the growth of gut bacteria and the
production of active metabolites was investigated. PomX, but
not punicalagin, significantly enhanced the growth of total
bacteria, as well as beneficial bifidobacteria and lactobacilli,
being the effect in contrast with previous results [46]. The
extract also increased the production of short chain fatty
acids, acetate, butyrate, and propionate [46], compounds
that are related to inhibition of preneoplastic proliferation
and acceleration of conversion of cholesterol into bile acids
[43]. As concerns the metabolism of PG ellagitannins, while
punicalagin was not detected in the fermentation media at
any collection time, after 10 hrs of incubation with PomX
there was a pick of ellagic acid (EA) that disappeared when
dibenzopyranones urolithins A, C, and D appeared [46].
Urolithin B was not detected in small intestine, suggesting
that ETs metabolism occurs in the colon as well, and the for-
mation of this compound is the last step of ETs metabolism.
Both urolithins C and D as well as urolithin A demon-
strated a high antioxidant activity in vitro (IC
50
0.16, 0.33,
and 13.6 𝜇M, resp. for urolithin C, D, and A) [47], but what
are the effects of PG metabolites on intestinal inflammation?
In the first study, the antiphlogistic effects of EA (50𝜇M)
were evaluated in Caco-2 differentiated cells treated with a
mixture of proinflammatory stimuli (IL-1𝛽, TNF-𝛼, IFN-𝛾,
and LPS) on secretion and mRNA expression of different
inflammatory biomarkers (IL-6, IL-8, MCP-1, and IL-10).
EA decreased only MCP-1 and IL-8 secretion, but the effect
was not statistically significant, and no effect on the mRNA
levels of these cytokines was observed [48]. Nevertheless,
in the same study, EA downregulated the transcription of
some genes involved in intestinal inflammation, as STAT-3, a
transcription factor responsible for the persistent activation
of NF-𝜅B [48]. In another study, EA, urolithins A and B,
and a mixture of them, at a concentration achievable in the
intestinal lumen after PG consumption (10𝜇M for EA and
40 𝜇M for urolithins), inhibited the growth of Caco-2 cancer
cells, deactivating the ERK-signalling pathway [49]. Opposite
results were obtained in human normal colon fibroblast cell
line CCD18-Co treated with IL-1𝛽, as a proinflammatory
stimulus, and with different concentrations (1–10𝜇M) of EA
and urolithins A or B since neither urolithins nor EAwas able
to decrease the phosphorylation of p-ERK1/2 [50]. Myofi-
broblasts in the colon mucosa play an important role in the
intestinal inflammatory response even by releasing PGE
2
. In
the same study it was shown that urolithin A decreased PGE
2
production, downregulating COX-2 and mPGES-1 expres-
sions but not their enzymatic activity. Reduction of PGE
2
production by urolithins could be explained by the inhibition
of NF-𝜅B activation and p38 MAPK pathway [50]. No
anti-inflammatory effects were seen with EA [50]. Authors
hypothesized that the anti-flogistic activity demonstrated by
urolithinsmight be due to a receptor-mediated effect, because
no metabolites were found in cell media or intracellular
extracts after incubation of cells with urolithins A, B or
EA [50]. Using the same cellular model of human colon
fibroblasts treated with IL-1𝛽 or TNF-𝛼 as proinflammatory
stimuli and urolithins A (40 𝜇M), B (5 𝜇M) or EA (1𝜇M), it
was demonstrated that all these metabolites inhibit two criti-
cal processes of inflammatory response: fibroblast migration
and monocyte adhesion. A mixture of urolithins A, B and
EA completely abolished IL-1𝛽 induction by PGE
2
, and this
activity was mainly due to urolithin A [51], in agreement with
another previous study [50]. The effect was not maintained
when TNF𝛼 was used as a stimulus, thus indicating that
PG metabolites could explain their action by a challenge-
dependent pathway [51]. PAI-1 is another molecule deeply
associated with inflammatory status of the intestinal mucosa,
whose expression is highly induced by IL-1𝛽 and TNF𝛼 and
is strictly related to fibroblast migration. The metabolites
mixture and urolithin A downregulated PAI-1 expression and
exerted also a preventive effect inhibiting some factors of
the PDGF family, known to be involved in cell migration
[51]. During inflammation, the presence of cytokines such
as IL-1𝛽 and TNF-𝛼 induces the expression of chemokines,
in particular IL-8, and adhesion molecules (e.g., ICAM-1
and VCAM-1) in colonic subepithelial myofibroblasts, thus
favouring monocyte infiltration and adhesion. The mixture
of metabolites reduced monocyte migration inhibiting IL-8
secretion induced by TNF𝛼 and ICAM-1 and VCAM-1 levels
after stimulation with IL-1𝛽 [51].
4.2. Animal Studies. There are two main standardized meth-
ods to produce an experimental animal model of IBD: (i) oral
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administration of dextran sulphate sodium (DSS) in drinking
water; (ii) intracolonic administration of trinitrobenzene
sulfonic acid (TNBS). The use of DSS method mimics the
development of UC, while symptoms manifested after TNBS
treatment present the clinical and morphological features of
CD.
In a rat model of DSS-induced UC, oral administration
of EA using colonic delivering microsphere (containing 1–
10mg/kg of EA) significantly reduced the severity of colonic
lesions and the shortness of colonic length. This activity
could be accounted by the antioxidative action of EA, as
demonstrated by the decreased myeloperoxidase (MPO)
activity and lipid peroxidation in the colonic mucosa of
animals treated with EA microspheres [52]. These results
were confirmed in another study, which showed that a
PG hydroalcoholic extract (100–200mg/kg) from flowers as
well as the ellagic acid-rich fraction attenuated DSS-induced
UC in mice, reducing colonic MPO activity and oxidative
markers [53]. In addition to the antioxidant effect, another
mechanism proposed for the anti-ulcerative properties of
EA was the stabilization of mast cells. Mast cells play an
important role in phlogistic processes by releasing many
proinflammatory factors, as histamine. DSS administration
in mice was also associated with an increase in histamine
content in colonic tissue, indicating mast cell degranulation.
Hydroalcoholic extract of PG (methanol : water 3 : 1) and its
ellagic acid-rich fraction significantly attenuated the DSS-
induced increase in the histamine level, suggesting a capacity
to stabilize mast cells degranulation [53]. The molecular
mechanisms underlying the anti-inflammatory activity of
EA in the gut were clarified in a study devoted to the
effect of this polyphenol on colon carcinogenesis [54]: EA
(60mg/kg), administered per os for 30 weeks in a rat model
of colon cancer, reduced inflammatory status decreasing the
expression and the production of COX-2, iNOS, IL-6, and
TNF-𝛼 through the inhibition of NF-𝜅B system [54]. The
same mechanism was confirmed in two studies analysing the
anti-flogistic effect of EA in TNBS-induced colitis in rats: (i)
in the first it was demonstrated that administration of EA
(10-20mg/kg) by gavage before and after induction of acute
colitis diminished the severity and extension of the intestinal
injuries and inhibitedMPO activity, in agreement with previ-
ous studies [52, 53]. It was also shown that treatment with EA
was able to reduce the neutrophilic infiltration and to increase
the production of mucus in globet cells. All these anti-
inflammatory effects might be explained by the reduction of
the expression of COX-2 and iNOS, through the inhibition
of NF-𝜅B-mediated transcriptional activation and preventing
p38, JNK and ERK-1/2 MAPKs phosphorilation [55]; (ii) the
second study analysed EA effect in a model of chronic colitis.
Chronic oral administration of a commercial PG fruit extract
(250–500mg/kg) with or without the enrichment with EA
(10mg/kg) was able to reduce inflammatory symptoms and
histological injuries, diminishing MPO activity, TNF-𝛼 pro-
duction, and reducing COX-2 and iNOS expression through
the inhibition of MAPKs and NF-𝜅B, but not PPAR-𝛾-
signalling pathways [56].
In a rat model of UC induced by 2,4-dinitrochloroben-
zene (DNCB) and acetic acid, intragastric administration of
an aqueous extract from PG peel (200–800mg/kg) relieved
diarrheic and ulcerative symptoms, decreasing MPO activity,
lipid peroxidation, IL-1𝛽, and TNF-𝛼 [57].
In another study, the PG peel extract (PPE) demonstrated
also to downregulate the expression of inflammatory genes
(COX-2, IL-6, and IL-1𝛽) in colonic and adipose tissues from
obese mice fed with a high-fat diet [58]. The same extract
possessed also a prebiotic effect, modulating gut microbiota
toward bifidobacteria [58], which are bacteria showing high
anti-flogistic activity in the intestinal tract [59]. Moreover, it
was demonstrated in vitro that gut bacteria could contribute
to the anti-inflammatory effects of PG extracts through
their capacity to metabolize polyphenols to bioavailable and
biological active urolithins [50]. To assess whether anti-
flogistic properties seen with PPE were due to ETs content or
to their microbiota-derived urolithins, a rat model of DSS-
induced colitis was fed with PG peel extract (250mg/kg)
or urolithin A (15mg/kg) for 25 days before administration
of DSS. In rats fed with PPE and urolithins A, the number
of bifidobacteria and lactobacilli increased, and the effect
was maintained after DSS administration only in urolithin
A-fed group. Both PPE and urolithin A increased also the
count of Clostridium probiotic strains and maintained it after
colitis induction, preventing the colonization and invasion of
colonic tissue by pathogenic enterobacteria [60]. Treatment
with PPE andurolithinA exerted the same anti-inflammatory
effects, downregulating PGE
2
production as well as iNOS
induction and NO levels; however, in the case of PPE, these
properties seemed not to be enough to protect the colonic
architecture [60]. Another interesting aspect is the evaluation
of metabolic fate of PPE after microbiota metabolism. In
fact PG metabolism in rats with colitis was shown to be
different from those without colon inflammation: the phe-
nolic profile of faeces of PPE-fed rats showed the presence
of ellagic acid and even punicalagin contained in PPE and
traces of urolithin A, while only urolithins were found in
faeces of healthy PPE-fed rats [60]. The low metabolism
exerted by gut microbiota in an inflammation context is
an important consideration studying the effects of phenolic
compounds. In fact, as previously demonstrated, in the pres-
ence of an inflammatory status they can reach, without any
metabolic transformation, the intestinal lumen and directly
exert their anti-inflammatory activity. In conclusion, the anti-
inflammatory properties shown by PG in the IBD model
could be explained by a synergic activity of urolithins, the
main active compound responsible for PG anti-inflammatory
effects in healthy subjects, with ETs and EA; however, the
increase in prebiotic bacteria by both PPE and urolithin A
or both these hypotheses taken together cannot be excluded
[60].
Pomegranate seed oil (PSO) is predominantly composed
of triglycerides containing unsaturated fatty acids, as con-
jugated linolenic acids, oleic acid, linolenic acid, palmitic
acid, and stearic acid. The major conjugated linolenic acid
in PSO (representing 60 to 80% of total fatty acids) is
punicic acid (PuA). Increasing evidence suggested that fatty
acids with conjugated double bonds, such as PuA, exert
beneficial effects in inflammation and some types of cancer
[61, 62]. Different in vivo studies assessed the effects of
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PG seed oil and PuA on intestinal inflammation. Oral
administration of PuA (800 𝜇g/mL) or PG seed oil (2%)
before TNBS injection in a colitis rat model ameliorated
ulceration status and tissue damage, limiting neutrophil acti-
vation and lipid peroxidation [63]. Molecular mechanisms
underlying these anti-inflammatory effects were clarified by
in vitro studies on human neutrophils. PuA (10 𝜇M) exerted a
strong anti-oxidant activity, inhibiting TNF-𝛼-induced ROS
and NADPH oxidase production by neutrophils, through
the inhibition of p47phox phosphorilation and p38 MAPK
activation [63]. Treatment with PuA prevented also TNF-
𝛼 and bacterial fMLP-induced neutrophil degranulation,
resulting in reduced MPO release and lower tissue injuries
[63]. In another study it was demonstrated that pretreatment
with PuA (45–80mg/die) to an IL-10−/− IBD mice model
ameliorated clinical symptoms, while it was not able to exert
any effect if administered after IBD development [64]. PuA
upregulated colonic PPAR-𝛿 activation and suppressed TNF-
𝛼 and MCP-1 expressions. Since effects of PuA disappeared
in IL-10 and PPAR-𝛾 or -𝛿 double-knock-out mice, it was
hypothesized that the pure compound exerted its action
through PPAR-𝛾 and -𝛿 pathways [64]. This conclusion was
in agreementwith previous results demonstrating that PPARs
represent important targets of dietary lipids, mediating the
maintenance of intestinal homeostasis. Moreover, PPAR-𝛾
expression results also in therapeutic benefits in the DSS
colitis model [65], producing the same effects seen with PuA.
PSO was shown to be effective also in a model of necrotizing
enterocolitis (NEC). This disease is the major cause of mor-
bidity andmortality in premature infants and is characterized
by a dysregulation of inflammatory cytokines in the intestinal
mucosa and an impaired production of mucins (as Muc2)
and trefoil factors (Tff) by lamina propria. Treatment with
PSO (1.5% w/w) of a neonatal model of NEC rats reduced the
incidence and severity of necrotizing colitis, protecting the
epithelial barrier and preserving the intestinal integrity [66].
PSO decreased IL-6, IL-8, IL-23, IL-12, and TNF-𝛼 mRNA
levels as well and downregulated the inflammatory response
in the developing intestinal mucosa [66].
Antidiarrhoeal Effects. Diarrhoea is one of the major symp-
toms of IBDs, mainly caused by inflammation and an
increased intestinal transit leading to a reduction in water
and electrolytes absorption. Two studies described the in vivo
antidiarrhoeal effect of PG. Intraperitoneal injection of an
aqueous extract of PG peels (100–400mg/kg) as well as orally
administration of a crude methanolic extract from PG rind
(200–400mg/kg) diminished diarrhoea induced by castor oil
administration in a rat model [67, 68]. PG aqueous extract
reduced in a dose-dependent way intestinal weight and
motility, inhibiting also the spontaneous and acetylcholine-
induced ileum contractions. Hypothesis formulated for this
antidiarrhoeal activity included (i) an increase of reabsorp-
tion of water and NaCl, reducing intestinal motility and (ii)
a decrease of cytosolic calcium, either by inhibiting Ca2+
influx or Ca2+ release from intracellular stores, resulting in
relaxation of rat ileal smoothmuscle [68]. On the other hand,
PG methanolic extract exerted a potent antioxidant activity
(IC
50
11.7 𝜇g/mL) and significantly scavenged nitric oxide
(IC
50
12.5 𝜇g/mL), a molecule involved in the diarrhoeal
effect induced by castor oil. Retardation of intestinal transit
demonstrated by PG crude extract might be explained with
an increased absorption of water and electrolyte, resulting in
a diminished number of wet faeces [67].
5. Conclusions
Few in vitro studies have been performed with PG peel
extracts to evaluate anti-H. pylori activity. These extracts
are able to reduce significantly the growth of this pathogen,
which is considered the aetiological agent mainly responsible
for human gastritis.
In vivo studies performed on the whole fruit or juice, peel,
and flowers demonstrate high antiulcer effect in a variety of
animal models. EA was found to be the main component
responsible for this effect, although other individual ETs,
which have not yet been studied, could contribute to the
biological activity of the mixture. With the exception of EA,
the effect of the pure compounds at the gastric level was not
investigated; this should be carefully considered for the future
studies, since these molecules appear to be unmodified at the
gastric level. Conversely, the positive effect of EA has been
widely demonstrated, and the effect is corroborated by other
studies performed on other plants: ethanolic extract from
Ficus glomerata fruit (FGE) contained 0.36% w/w of EA and
showed significant dose-dependent anti-ulcerogenic effect
in different models of induced gastritis (pylorus ligation,
ethanol, and cold stress) [69]; moreover, the hydroalcoholic
extract ofAnogeissus latifolia (50% alcohol) containing 0.25%
w/wof EAhas been shown to possess gastroprotective activity
[70] due to the presence of EA. In addition, methanol stem
bark extract of Lafoensia pacari containing 23.4% of EA
showed gastroprotective and ulcer-healing effects in animal
models strictly associated to the presence of great amounts
of EA in the extract [71], and an improvement of the gastric
symptoms in patients with H. pylori gastritis was observed
[72]. The mechanism of action by which EA shows antiulcer
activity is partially attributed to the inhibitory effect on the
gastric H+, K+-ATPase, in addition to the anti-H. pylori
activity [38].
Unfortunately, no clinical studies coping with the anti-
inflammatory activity of PG at the gastric level have been
found, thus suggesting that the effect of the extracts and
individual compounds in this area need to be elucidated. In
particular, it is necessary to draw clinical trials considering
the effects of PG extracts in patients with H. pylori-induced
gastritis, alone or in combination with antibiotics.
Different preparations of PG, including extracts from
peels, flowers, and seeds, in addition to the juice, show a
significant anti-inflammatory activity in the gut. From all
the studies taken into consideration in the present paper,
some conclusions can be drawn. First of all, the pure
compounds occurring in PG fruits seem to act through
different pathways. Oil derived from PG seeds and its major
component PuA could inhibit the expression of proinflam-
matory cytokines (such as IL-6, IL-8, IL-23, IL-12, and
TNF-𝛼) through the modulation of PPAR-𝛾 and -𝛿. This is
Evidence-Based Complementary and Alternative Medicine 9
not true for PG peel extracts, as well as their components
punicalagins and EA, since they do not show any effect on
PPAR signalling; conversely, the main effect is due to the
inhibition of the expression and secretion of several inflam-
matory mediators (i.e., IL-6, IL-8, MCP-1, iNOS, COX-2,
and PGE
2
). The inhibitory effect is ascribed to the inhibition
of the NF-𝜅B pathway and involves the MAPKs system as
well. This effect was confirmed both in vitro and in vivo
for the extracts and the pure compound punicalagin, while
contradictory results were found for EA, since it seems to
be effective only in studies performed in vivo. This might
be explained considering the metabolic fate of PG phenolic
compounds. In fact, different studies demonstrate a strong
interaction between gut microbiota and PG polyphenols
(i.e., EA) that are metabolized by intestinal microflora to
urolithins. These metabolites themselves could modulate gut
microbiota, enhancing the growth of beneficial strains in
spite of pathogenic ones. Among urolithins, urolithins A
has been shown to possess a significant anti-inflammatory
activity both in vitro and in vivo, thus suggesting that this
compound, and not its precursor EA, could be the main
responsible for the anti-inflammatory properties observed
with PG extracts in the gut. However it has been also
showed that the inflammatory status alters the composition of
intestinalmicrobiota, changing itsmetabolic capacity and the
bioavailability of phenolic compounds [60].This statement is
corroborated by observation that, after consumption of PG
extract, the phenolic profile of faeces obtained from healthy
and DSS-fed rats is deeply changed: in normal conditions
EA and punicalagin are completely metabolized to urolithins
A, whereas in inflammatory conditions they can be found
unmodified in the colon [60]. This suggests that biological
effects of urolithins, and consequently PG, could be strictly
related to the composition of individual microbiota and to
the intestinal inflammatory status. For this reason, although
the studies reported herein seem to recommend PG con-
sumption to prevent or treat gastrointestinal inflammation,
future clinical studies on anti-inflammatory activity at the
gastrointestinal tract are necessary to clarify the beneficial
effects of PG for human health.
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